TuHURA secures $50M credit facility, extends cash runway to 2028 amid Phase 3 trial launch

Filed May 15, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 15, 2025 · ~2 min read

Key Changes

• high

  Company entered $50M revolving credit facility with affiliate of largest stockholder at 12% interest, secured by substantially all assets including IP. Facility includes royalty on IFx-2.0 sales and 75% profit sweep once commercialization begins, significantly constraining future cash flow.

  Risk Factors: Secured Credit Facility verify on EDGAR →
• high

  Cash runway extended from Q4 2025 to end of 2028, reflecting December 2025 equity raise ($15.6M gross), new credit facility, and ATM program. Company initiated Phase 3 trial for IFx-2.0 in Merkel cell carcinoma in June 2025 using FDA accelerated approval pathway.

  MD&A: Liquidity and Clinical Milestones verify on EDGAR →
• high

  Completed Kineta acquisition in June 2025, adding TBS-2025 anti-VISTA antibody to pipeline. Company plans Phase 2 trial in mutNPM1 AML, diversifying beyond IFx-2.0 into checkpoint inhibitor space targeting myeloid-driven immunosuppression.

  MD&A: Pipeline Expansion verify on EDGAR →